1.. Introduction
================

Signals from the overhead pacemaker of the circadian clock, the SCN, mediate the oscillation on a cellular level through clock gene expression and feedback ([@b1-mco-0-0-1518]). A disruption in these signaling pathways may have a crucial influence on the organism affected. Circadian genes may be involved in regulating cancer-related pathways, including cell proliferation, DNA damage response, and apoptosis ([@b2-mco-0-0-1518]). Cancer-related genes like *c-myc* and *p53* exhibit a circadian rhythm *in vivo* ([@b3-mco-0-0-1518],[@b4-mco-0-0-1518]). Oncogenic activity such as excessive cell proliferation, loss of DNA damage control and increased tumor development has been detected in mice with a loss of functioning circadian genes ([@b4-mco-0-0-1518]). The lifestyle in the twenty-first century has changed due to more industrialization of society, which has altered the endogenous circadian rhythm in \~50% of the world\'s population. This, among other reasons, has led to increased development of cancer throughout the world ([@b5-mco-0-0-1518]). There are studies showing the effect of dysfunctional circadian machinery in humans, for example mutations, non-standard expression, and translocation of clock genes, which has led to different cancer types including breast, colorectal, gastric, kidney, lung, prostate, pancreatic, and oral cancer ([@b6-mco-0-0-1518]). The circadian clock and the cell cycle share some common features in molecular pathways and theoretical stages. It has been hypothesized that clock genes have a crucial role in the cell cycle and with this role they are highly involved in tumorigenesis ([@b4-mco-0-0-1518]). The underlying molecular mechanisms and the role of clock genes in oral carcinogenesis is elusive. The aim of this review is to summarize the current state of knowledge and to provide insight to guide future research on involvement of clock genes in oral cancer.

2.. Circadian clock biology
===========================

### Physiology of the circadian clock

The circadian clock is an endogenous timekeeping system shared by most organisms. Although there are some differences between species, the underlying molecular mechanisms of the circadian clock are very similar ([@b7-mco-0-0-1518]). The ability to adapt to a continuously changing environment is an essential key to selective advantage for living creatures to survive and thrive. The circadian clock system is one of these adapting abilities, which organisms have acquired in order to synchronize their daily behavior and internal mechanisms with the most profound environmental signal: The circadian light cycle of 24 h. Body temperature, feeding, hormonal levels, and the sleep-wake cycle all varies synchronized with light-dark cycle ([@b8-mco-0-0-1518]). Another great ability of this system is adjustment to the 24 h cycle showing a crucial plastic capacity ([@b9-mco-0-0-1518]). There is a hypothesis called 'escape from UV', which is based on the S phase of the cell cycle, which is during night-time. It suggests that ancient lifeforms have adapted to the environment by limiting this UV-sensitive phase of the cycle to nighttime in order to avoid DNA-damage ([@b10-mco-0-0-1518]).

The circadian clock system consists of almost as many individual clocks as there are cells. It is based on different levels and controls the whole rhythmicity of the organism ([@b11-mco-0-0-1518]). In mammals there is a central pacemaker in the suprachiasmatic nucleus (SCN) of the hypothalamus consisting of \~15,000 neurons ([@b12-mco-0-0-1518]). The input to this central pacemaker comes through different pathways. The primarily input, i.e. light, is registered in the retina by a subset of melanopsin-expressing retinal ganglions and accesses the SCN via the retino-hypothalamic tract (RHT). From the SCN there are output pathways leading to the whole body ([@b11-mco-0-0-1518],[@b13-mco-0-0-1518],[@b14-mco-0-0-1518]). These feeding pathways are regulated by interlocked transcription-translation feedback loops (TTFLs) ([@b15-mco-0-0-1518]), where the clock gene family exerts an important role. In *Drosophila* and zebrafish, light has a direct influence on the circadian behavior of the peripheral cells ([@b12-mco-0-0-1518],[@b16-mco-0-0-1518]), whereas in mammals the clock genes in peripheral tissues are not light sensitive. Here, they maintain and regulate TTFLs in almost every cell of the body by feeding pathways from the SCN and other molecular processes ([@b11-mco-0-0-1518]). One of these transcription/translation feedback loops consists of the heterodimeric transcription complex: CLOCK/BMAL1, which in the morning binds to the E-boxes in the promoter region of genes expressing Period proteins (PER1, PER2, and PER3) and Cryptochrome proteins (CRY1 and CRY2). When these proteins accumulate, and reach an acute concentration in cytoplasm, factors like Skp1-Cullin-F-box protein (SCF) E3 ubiquitin ligase complexes, caseinkinase 1ε/δ (CK1ε/δ), and AMP kinase (AMPK) lead to the formation of the PER/CRY complex. These protein complexes translocate into the nucleus and reduce the activity of CLOCK/BMAL1 by direct protein-protein interaction by night, i.e., a negative feedback loop. The robustness of this feedback loop is ensured by a secondary mechanism where two subfamilies of nuclear hormone receptors Rev-erb and Ror, regulate the transcription of Bmal1 and thereby directly regulate the core feedback loop ([Fig. 1](#f1-mco-0-0-1518){ref-type="fig"}) ([@b17-mco-0-0-1518]--[@b19-mco-0-0-1518]). Further, chromatin remodeling and posttranslational modifications ensure the regulation required for maintenance of the circadian rhythm ([@b8-mco-0-0-1518],[@b20-mco-0-0-1518],[@b21-mco-0-0-1518]). A study based on systematic mathematical and computational analysis of the biological rhythms has revealed that oscillations are created by the negative feedback signals, whereas the frequency of these oscillations is adjusted by the positive feedback signals without altering the amplitude of the oscillation ([@b22-mco-0-0-1518]). Another study has shown that the SCN plays a more significant role in synchronizing the peripheral clocks than regulating their oscillation, which suggests a more cell-independent model of the system ([@b23-mco-0-0-1518],[@b24-mco-0-0-1518]). Accordingly, most circadian genes, except for *clock* and *CKI*ε, have a rhythmic expression in periods of 24 h. The clock/Bmal1 complex regulates the transcription of many other genes in addition to clock genes. A circadian oscillation is observed in the transcription of \>10% of mammalian genes, and naturally the clock gene family exhibits an important role in many physiological functions such as food intake, body temperature, metabolism and synthesis and release of hormones ([@b25-mco-0-0-1518]--[@b27-mco-0-0-1518]). Circadian regulators, being directly involved in the circadian machinery, are suggested to control cell cycle. For example, CLOCK/BMAL1 regulates cell cycle gene Wee1 being important in the G2/M phase, 12c-myc in the G0/G1 phase and Cyclin D1, which is important in the G1/S phase ([@b3-mco-0-0-1518]). Moreover, an interaction is detected between PER1 and checkpoint proteins such as ATM and Chk2 and 17 ([@b28-mco-0-0-1518]).

### Disruption in the circadian clock and its consequences

It has been suggested that disease caused by circadian rhythm alterations is due to gene dosage changes and failure in controlling gene dosages in TTFLs ([@b29-mco-0-0-1518]). Alterations and disruption of the circadian clock are a more common problem nowadays due to the industrialization of our society where artificial lighting, working night shifts, and rapid long-distance travelling through several time zones are common features. This is speculated to be directly linked to the increasingly higher risk of acquiring a number of health problems and diseases including cancer ([@b30-mco-0-0-1518]). Epidemiologic studies of circadian clock alterations have suggested a link between cardiovascular, metabolic, gastrointestinal, and mental disorders as well as numerous cancer forms such as breast, ovarian, lung, pancreatic, prostate, colorectal, and endometrial cancers, non-Hodgkin\'s lymphoma (NHL), osteosarcoma, acute myeloid leukemia (AML), head and neck squamous cell carcinoma and hepatocellular carcinoma ([@b31-mco-0-0-1518]--[@b45-mco-0-0-1518]). The risk of acquiring cancer alters with the frequency and duration of disruption of the endogenous circadian clock. ([@b40-mco-0-0-1518],[@b46-mco-0-0-1518]--[@b49-mco-0-0-1518]).

The hypothesis of artificial lighting altering the circadian clock and leading to a higher cancer risk is further strengthened by the findings in visually impaired individuals that were not affected by light input and depended on other inputs for regulating their endogenous clock. Studies have shown a lower cancer risk for these individuals than others in the same environment ([@b50-mco-0-0-1518]--[@b52-mco-0-0-1518]). In 2007, research and evidence gathered resulted in classifying 'shiftwork that involves circadian disruption' as a probable carcinogen by the International Agency for Research in Cancer ([@b44-mco-0-0-1518]).

The disruption of the circadian clock has not only been shown to increase the risk of disease, but also to affect the prognosis and treatment outcome of patients. Studies have demonstrated that variation in circadian cortisol value in blood and sleeping patterns of the patients with metastatic breast, colorectal, or lung cancer are linked to overall survival of these patients ([@b53-mco-0-0-1518]--[@b59-mco-0-0-1518]). Although these findings suggest that the circadian clock undergoes significant changes in human tumorigenesis, the direct links between aberrant circadian clock gene expression and human malignancies, including oral and head and neck carcinomas, remain largely elusive. The present review focuses on the role of clock genes in oral squamous cell cancer.

3.. Clock genes in cancer
=========================

### Effects of clock gene expression level in cancer tissue

The molecular process in how clock genes expression levels prevent or enhance tumorigenesis is not yet fully understood; however, several studies have registered a correlation between different expression levels of each clock gene and different cancer types. NPAS2 has shown a significant association with a lack of metastasis and survival prognosis in breast cancer patients ([@b60-mco-0-0-1518]--[@b62-mco-0-0-1518]). Similar results were presented in colorectal cancer, and decreased expression of NPAS2 was strongly correlated to tumor size, TNM stage and metastasis rate ([@b63-mco-0-0-1518]). In ERα-positive breast cancer tissue the high expression of the *clock* gene was reduced through a knockout technique and a reduction in proliferation was observed. In contrast, administration of estrogen resulted in increased expression of *clock* and the proliferation of breast cancer cells ([@b64-mco-0-0-1518]). Also, in colorectal cancer a higher expression of *clock* is registered in diseased tissue ([@b65-mco-0-0-1518]). These findings present a diagnostic value for both genes and the adverse effects of two different clock genes where a high level of NPAS2 expression is correlated to better prognosis whereas a high level of *clock* expression correlates to increased proliferation of cancerous tissue.

A lower expression level of PER1, PER2, and PER3 has been registered in diseased tissue compared to normal adjacent tissue in breast cancer, prostate cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric cancer, kidney cancer and non-small-cell lung cancer ([@b61-mco-0-0-1518],[@b66-mco-0-0-1518]--[@b71-mco-0-0-1518]). PER1 and PER2 have shown a tumor-suppressing effect in a number of studies. Higher expression of PER2 in breast cancer tissue correlated with a lack of metastasis ([@b61-mco-0-0-1518]). In a study where the PER2 expression was downregulated, a substantial increase in tumor growth rate and higher proliferation in diseased cells were observed both *in vivo* and *in vitro* ([@b72-mco-0-0-1518]). In gastric cancer tissue a suppressing role of PER1 and PER2 on tumor progression and metastasis was registered and a low expression of PER1 and PER2 was correlated with poorer prognosis ([@b64-mco-0-0-1518]). Overexpression of PER1 showed a great inhibition of growth and stimulated apoptosis in prostate cancer cell lines ([@b71-mco-0-0-1518]). A correlation between decreased levels of PER1 and a lower survival rate and liver metastasis in gastric cancer patients has also been detected ([@b65-mco-0-0-1518],[@b66-mco-0-0-1518]).

A link has been discovered between CRY2 and breast cancer progression and prognosis where lower expression levels were registered in diseased tissue ([@b73-mco-0-0-1518]). Moreover, the *CRY1* gene was associated with fatal prostate cancer ([@b74-mco-0-0-1518]). Results from an animal study with *Bmal1* knockout mice showed that circadian behavior in total darkness came to a complete stop ([@b75-mco-0-0-1518]). Research has registered lower expression of BMAL1 in diseased tissue compared to normal adjacent tissue in patients with colorectal cancer, pancreatic cancer, and pancreatic ductal adenocarcinoma ([@b67-mco-0-0-1518],[@b76-mco-0-0-1518],[@b77-mco-0-0-1518]). A knockdown of *Bmal1* in pancreatic cancer cell lines led to increased cell proliferation and decreased apoptosis ([@b77-mco-0-0-1518]). *In vivo* and *in vitro* studies of colorectal cancer patients show that a higher level of BMAL1 expression correlates to less tumor cell proliferation and higher survival ([@b76-mco-0-0-1518]). Collectively, these data open avenues for novel diagnostic and therapeutic models for different cancer forms and prove the need for, and importance of, further research on clock genes.

4.. Clock genes in oral cancer
==============================

### Oral cancer

Worldwide, almost 300,000 people are annually diagnosed with oral cancer, which makes it the 10th most common type of cancer ([@b78-mco-0-0-1518]). Oral cancer incidence and mortality rates vary widely across the world, and the highest rates are generally registered in a few developing countries, i.e., Sri Lanka, India, Pakistan, and Bangladesh ([@b79-mco-0-0-1518]). The etiology of oral cancer is multifactorial. The main risk factors are tobacco use and alcohol consumption with combined multiplicative effects possibly leading to DNA damage or mutations. Human papilloma virus infection and genetic polymorphism can also be mentioned as risk factors ([@b80-mco-0-0-1518]--[@b82-mco-0-0-1518]). Men are overrepresented in this patient group and high age and lower socioeconomic status may have an impact ([@b83-mco-0-0-1518]).

Oral squamous cell carcinoma (OSCC), one type of oral cancer, is the eighth most common cancer worldwide ([@b84-mco-0-0-1518],[@b85-mco-0-0-1518]). Over 90% of oral malignancies are squamous cell carcinomas and its variants ([@b45-mco-0-0-1518],[@b86-mco-0-0-1518]). This cancer type usually emerges from the tongue, floor of the mouth, buccal mucosa, gingiva and hard palate. Cancer located in the tongue is associated with poorer prognosis ([@b87-mco-0-0-1518],[@b88-mco-0-0-1518]).

### Clock genes in healthy oral mucosa

Clock genes have been detected in healthy oral mucosa and their diurnal oscillations are mapped ([@b89-mco-0-0-1518],[@b90-mco-0-0-1518]). Rhythmical oscillation of the genes and their different peaks has been shown to occur simultaneously with different phases of the cell-cycle. PER1 peaked simultaneously as p53, which is a G1-marker and an important gene in oncogenesis. BMAL1 peaked simultaneously with the M-phase marker cyclinβ1 ([@b90-mco-0-0-1518]). Studies have confirmed that cyclinβ1 and p53 are targets of human clock genes where loss of BMAL1 reduces the expression of p53 along with PER1, PER2, and PER3. It has also been hypothesized that p53 is involved in regulating PER2 expression by blocking the CLOCK/BMAL1 complex from binding to a promotor region ([@b77-mco-0-0-1518],[@b91-mco-0-0-1518]--[@b93-mco-0-0-1518]). This further supports the theory that there is a connection between clock gene activity and the cell cycle ([@b2-mco-0-0-1518]).

### Clock genes and oral squamous cell carcinoma

Clock genes have a clear role in cancer development, prognosis, and therapy. From the perspective of biological rhythms, focusing on clock genes may provide novel ideas and methods for a better understanding of the occurrence and development of tumors, and for individualized treatment of cancer. So far, the results suggest that the PER1 gene may be used as a marker to determine clinical staging and the metastatic risk, and as a novel target for the prevention and treatment of oral cancer. ([@b94-mco-0-0-1518]--[@b96-mco-0-0-1518]) However, future studies are warranted in order to concentrate on the translational and post-translational levels and to illustrate the molecular function and the regulatory effects in the clock gene network and the tumor-suppression mechanisms of PER1, providing new and effective molecular targets for the treatment of oral cancer.

A few studies have investigated the role of clock genes in OSCCs ([Table I](#tI-mco-0-0-1518){ref-type="table"}). It has been demonstrated that OSCC *in vivo* development undergoes circadian oscillation in relation to tumor volume and proliferation rate ([@b97-mco-0-0-1518]). Hsu *et al* observed similar results in head and neck squamous cell carcinoma (HNSCC). Cancerous and non-cancerous adjacent tissues from 40 patients diagnosed with HNSCC were obtained, and they detected the expression of nine core clock genes, *PER1, PER2, PER3, CRY1, CRY2, CK1*ε, *TIM, CLOCK*, and *BMAL1*. The results also showed a significantly decreased expression of *PER1, PER2, PER3*, *BMAL1*, and especially *CRY2* in cancerous tissue compared to healthy adjacent tissue. In more advanced stages, they observed lower expression levels of *PER3*, *CRY2*, and *BMAL1*. Downregulation of *PER1* and *PER3* correlated with poor survival in these patients ([@b45-mco-0-0-1518]).

*PER1* expression was detected in 41 OSCC patients where diseased tissue was compared with healthy adjacent mucosa. In addition, the correlation with clinicopathological features was investigated in these patients. The results showed a significantly decreased level of expression in cancerous tissue compared to adjacent healthy tissue; also, the expression level decreased with the tumor progression. Patients with no lymph-node metastasis expressed a higher level of *PER1* than those with metastasis ([@b94-mco-0-0-1518]). It is suggested that the clock gene *PER1* possesses a tumor suppressing quality, which may have diagnostic and therapeutic use. *PER1* gene knockdown in OSCC cell line SCC15 led to immediate abnormal behavior in terms of cell growth, proliferation, apoptosis resistance, migration and invasion *in vitro*. Mice injected with these modified cells subcutaneously experienced enhanced tumor development ([@b95-mco-0-0-1518],[@b96-mco-0-0-1518]). Another interesting finding again is the connection between *PER1* and *p53*, where knockdown of *PER1* was followed by decreased expression of *p53*. Moreover, the daily oscillation of *PER1* and tumor-related genes such as *p53*, but also *VEGF* and *c-myc*, is correlated with cancer development ([@b98-mco-0-0-1518]). Suppression of *PER1* leads to disturbance in the cell cycle and inhibits DNA damage control, which again makes clock genes and *PER1* a key research subject in the field of carcinogenesis ([@b99-mco-0-0-1518]). The molecular mechanism behind the tumor-suppressing quality of PER1 is the regulation of the Cyclin-CDK-cyclin-dependent kinase inhibitor regulatory network ([@b100-mco-0-0-1518]). Tumorigenesis is highly due to disorders in the normal cell cycle, and maintaining a functional cell cycle is dependent on the Cyclin-CDK-cyclin-dependent kinase inhibitor regulatory network ([@b2-mco-0-0-1518]). Studies on the OSCC cell line SCC15 have shown decreased expression of PER1, leading to downstream regulation by increasing the level of CyclinD1, CyclinE, CyclinB1, CDK1, and WEE1 while decreasing the levels of P53, CyclinA2, P16, P21, and CDC25 ([@b100-mco-0-0-1518]). Knockdown of *PER1* led to a downregulation of the PER2, DEC1, DEC2, CRY1, CRY2, and NPAS2 mRNA level, while PER3, TIM, RORα, and REV-ERBα mRNA were upregulated ([@b96-mco-0-0-1518]). This suggests that *PER1* not only regulates the downstream genes, but it also plays a role in the synergy of the rest of the clock genes in the circadian machinery in SCC15 cell lines.

Investigation of the role of PER2 in OSCC cell line Tca8113 cells, showed a lower level of expression than in healthy tissue. The expression of PER2 was down regulated, and cell cycle, cell proliferation and apoptosis was analyzed using flow cytometry and RT-qPCR. The down-regulation of PER2 expression had a great effect on the CDK/CKI cell cycle network and altered the expression levels of many factors including decreasing p53. A significantly higher cell proliferation and lower apoptosis were observed ([@b101-mco-0-0-1518]). Tan *et al* investigated the circadian pattern of PER2 and various cell cycle genes in golden hamsters. PER2 and P53 had a decreased level while Cyclin D1, CDK1, and Cyclin B1 levels increased during cancer development ([@b102-mco-0-0-1518]).

Reports show that PER1 has a pro-apoptotic role in many cancer types, for example in human colon cancer and prostate cancer ([@b71-mco-0-0-1518],[@b99-mco-0-0-1518]). But it has also been reported that PER1 has an anti-apoptotic role in pancreatic and hepatocellular cancer cells ([@b103-mco-0-0-1518]). A pro-apoptotic role of PER1 is suggested in OSCCs, but in contrast, in the gingival cancer cell line CA9-22, PER1 had an increased level of expression in cancer cells compared to healthy gingival cells, while PER3 had a decreased level of expression in diseased cells compared to normal cells. An anti-apoptotic role was observed for PER1 and pro-apoptotic role for PER3 ([@b104-mco-0-0-1518]). These results emphasize the importance of the variation in cancer cell properties and indicate that the same gene may play a substantially different role in different parts of the body and that thorough research is crucial for obtaining useful results concerning cancer diagnosis and therapeutic methods.
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![Transcriptional/translational feedback loops (TTFL) model of the molecular clock in mammals. The positive arm of TTFL is constructed by the core clock genes, BMAL1 and CLOCK, which heterodimerize and bind to the E-box element on circadian target genes to activate transcription, including PER 1--3, CRY 1--2, ROR, Rev-Erb α and other genes in output pathways. The complex formed by Phospho-PER and CRY inhibits BMAL1/CLOCK-driven transcription, constructing the core negative feedback loop. ROR increases and Rev-Erb α inhibits the expression of BMAL1 and thus constructs a second feedback loop.](mco-08-02-0219-g00){#f1-mco-0-0-1518}

###### 

Clock genes and oral cancer.

  Authors, year        Cell type/origin                                                                           Methods                                                                                  Results/conclusions                                                                                                                                                                                                                                                                                          (Refs.)
  -------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------
  Zhao *et al*, 2016   *In vitro*: SCC15 cell line; *In vivo*: Nude mice                                          PER1 knockdown in SCC15 cells; *In vivo* tumerigenisity of SCC cells evaluated in mice   Enhanced proliferation, reduced apoptosis and enhanced the tumorigenic capacity of SCC15 cells *in vivo* and *in vitro*; mRNA expression of PER3, TIM, RORα and REV-ERBα was significantly up-regulated; mRNA expression of PER2, CRY1, CRY2 and NPAS2 was significantly down-regulated                      ([@b96-mco-0-0-1518])
  Fu *et al*, 2016     *In vitro*: SCC15 cell line; *In vivo*: Nude mice                                          Quantitative real-time PCR; *In vivo* tumerigenisity of SCC cells evaluated in mice      Increased expression of Cyclin D1, Cyclin E, Cyclin b1, CDK1 and WEE1; Decreased expression of P53, Cyclin A2, P16, P21, and CDC25; Fewer cells in S phase and more cells in G2/M phase; Enhanced proliferation and reduced apoptosis; Enhanced tumorigenicity of PER1 downregulated SCC15 cells *in vivo*   ([@b100-mco-0-0-1518])
  Li *et al*, 2016     *In vitro*: SCC15 cell line; *In vivo*: Nude mice                                          PER1 knockdown in SCC15 cells; *In vivo* tumerigenisity of SCC cells evaluated in mice   Profeleration, migration and invasion increased whereas apoptosis decreased; Up-regulated expression of tumorrelated genes; Enhanced *in vivo* tumerogenesis                                                                                                                                                 ([@b95-mco-0-0-1518])
  Wang *et al*, 2016   OSCC cell line Tca8113                                                                     Per2 downregulation; Quantitative real-time PCR                                            Increased Cyclin A2, B1 and D1, CDK4, CDK6 and E2F1; Decreased p53, p16 and p21; Increased profileration; Decreased apoptosis                                                                                                                                                                              ([@b101-mco-0-0-1518])
  Zhao *et al*, 2013   32 mice injected with human OSCC cell line BcaCD885                                        Measured tumor progression after 3 weeks                                                 Circadian rhythm in tumor volume and proliferative index; Not in apoptotic index                                                                                                                                                                                                                             ([@b97-mco-0-0-1518])
  Chen *et al*, 2012   Human cancerous and healthy adjacent tissue from 41 OSCC patients                          PER1 protein and mRNA expression and clinicopathological features                        Significantly decreased expression of PER1 in diseased tissue;Gradually decreased expression during cancer development                                                                                                                                                                                       ([@b94-mco-0-0-1518])
  Hsu *et al*, 2012    Human cancerous and noncancerous tissue from 40 HNSCC patients                             Quantitative real-time PCR                                                               PER1, PER2, PER3, CRY2, BMAL were significantly downregulated; The expression levels were most changed for CRY2                                                                                                                                                                                              ([@b45-mco-0-0-1518])
  Sato *et al*, 2011   Cell line from human gingival cancer CA9-22; Tumor and non tumor tissue from 13 patients   Knockdown and overexpression of PER1 and PER3; Quantitative real-time PCR                PER1 knockdown enhanced apoptosis while PER3 knockdown inhibited apoptosis in CA9-22; PER1 overrepresented in cancerous tissue; PER3 overrepresented in non cancerous tissue                                                                                                                                 ([@b104-mco-0-0-1518])

SCC, squamous cell carcinoma; OSCC, oral squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma.
